Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-MedSci.cn

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Wainberg, ZA; Enzinger, PC; Kang, YK; Yamaguchi, K; Qin, SK; Lee, KW; Oh, SC; Li, J; Turk, HM; Teixeira, AC; Cardellino, GG; Guardeno, R; Mitra, S; Yang, YS; Collins, H; Catenacci, DVT

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):

科室
- - 订阅+
  - 更多科室
工具
服务